Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 49
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
J Chem Phys ; 152(18): 184102, 2020 May 14.
Artigo em Inglês | MEDLINE | ID: mdl-32414274

RESUMO

Specialized computational chemistry packages have permanently reshaped the landscape of chemical and materials science by providing tools to support and guide experimental efforts and for the prediction of atomistic and electronic properties. In this regard, electronic structure packages have played a special role by using first-principle-driven methodologies to model complex chemical and materials processes. Over the past few decades, the rapid development of computing technologies and the tremendous increase in computational power have offered a unique chance to study complex transformations using sophisticated and predictive many-body techniques that describe correlated behavior of electrons in molecular and condensed phase systems at different levels of theory. In enabling these simulations, novel parallel algorithms have been able to take advantage of computational resources to address the polynomial scaling of electronic structure methods. In this paper, we briefly review the NWChem computational chemistry suite, including its history, design principles, parallel tools, current capabilities, outreach, and outlook.

2.
Med Phys ; 34(4): 1321-35, 2007 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17500463

RESUMO

This paper deals with the application of the adjoint transport theory in order to optimize Monte Carlo based radiotherapy treatment planning. The technique is applied to Boron Neutron Capture Therapy where most often mixed beams of neutrons and gammas are involved. In normal forward Monte Carlo simulations the particles start at a source and lose energy as they travel towards the region of interest, i.e., the designated point of detection. Conversely, with adjoint Monte Carlo simulations, the so-called adjoint particles start at the region of interest and gain energy as they travel towards the source where they are detected. In this respect, the particles travel backwards and the real source and real detector become the adjoint detector and adjoint source, respectively. At the adjoint detector, an adjoint function is obtained with which numerically the same result, e.g., dose or flux in the tumor, can be derived as with forward Monte Carlo. In many cases, the adjoint method is more efficient and by that is much quicker when, for example, the response in the tumor or organ at risk for many locations and orientations of the treatment beam around the patient is required. However, a problem occurs when the treatment beam is mono-directional as the probability of detecting adjoint Monte Carlo particles traversing the beam exit (detector plane in adjoint mode) in the negative direction of the incident beam is zero. This problem is addressed here and solved first with the use of next event estimators and second with the application of a Legendre expansion technique of the angular adjoint function. In the first approach, adjoint particles are tracked deterministically through a tube to a (adjoint) point detector far away from the geometric model. The adjoint particles will traverse the disk shaped entrance of this tube (the beam exit in the actual geometry) perpendicularly. This method is slow whenever many events are involved that are not contributing to the point detector, e.g., neutrons in a scattering medium. In the second approach, adjoint particles that traverse an adjoint shaped detector plane are used to estimate the Legendre coefficients for expansion of the angular adjoint function. This provides an estimate of the adjoint function for the direction normal to the detector plane. In a realistic head model, as described in this paper, which is surrounded by 1020 mono-directional neutron/gamma beams and from which the best ones are to be selected, the example calculates the neutron and gamma fluxes in ten tumors and ten organs at risk. For small diameter beams (5 cm), and with comparable relative errors, forward Monte Carlo is seen to be 1.5 times faster than the adjoint Monte Carlo techniques. For larger diameter neutron beams (10 and 15 cm), the Legendre technique is found to be 6 and 20 times faster, respectively. In the case of gammas alone, for the 10 and 15 cm diam beams, both adjoint Monte Carlo Legendre and point detector techniques are respectively 2 and 3 times faster than forward Monte Carlo.


Assuntos
Algoritmos , Terapia por Captura de Nêutron de Boro/métodos , Modelos Biológicos , Método de Monte Carlo , Radiometria/métodos , Planejamento da Radioterapia Assistida por Computador/métodos , Simulação por Computador , Humanos , Modelos Estatísticos , Dosagem Radioterapêutica
3.
Mol Cell Biol ; 9(6): 2477-86, 1989 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-2668734

RESUMO

We have identified the domain of the human c-myc protein (c-Myc) produced in Escherichia coli that is responsible for the ability of the protein to bind sequence-nonspecific DNA. Using analysis of binding of DNA by proteins transferred to nitrocellulose, DNA-cellulose chromatography, and a nitrocellulose filter binding assay, we examined the binding properties of c-Myc peptides generated by cyanogen bromide cleavage, of mutant c-Myc, and of proteins that fuse portions of c-Myc to staphylococcal protein A. The results of these analyses indicated that c-Myc amino acids 265 to 318 were responsible for DNA binding and that other regions of the protein (including a highly conserved basic region and a region containing the leucine zipper motif) were not required. Some mutant c-Mycs that did not bind DNA maintained rat embryo cell-cotransforming activity, which indicated that the c-Myc property of in vitro DNA binding was not essential for this activity. These mutants, however, were unable to transform established rat fibroblasts (Rat-1a cells) that were susceptible to transformation by wild-type c-Myc, although this lack of activity may not have been due to their inability to bind DNA.


Assuntos
Proteínas de Ligação a DNA/genética , DNA/metabolismo , Escherichia coli/genética , Proteínas Proto-Oncogênicas/genética , Sequência de Aminoácidos , Animais , Sequência de Bases , Cromatografia/métodos , Clonagem Molecular , Brometo de Cianogênio , Proteínas de Ligação a DNA/metabolismo , Humanos , Immunoblotting , Dados de Sequência Molecular , Mutação , Testes de Precipitina , Proteínas Proto-Oncogênicas/metabolismo , Proteínas Proto-Oncogênicas c-myc , Ratos , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/metabolismo , Replicon , Proteína Estafilocócica A/genética
4.
Mol Cell Biol ; 18(12): 7020-9, 1998 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-9819389

RESUMO

ATF2 belongs to the bZIP family of transcription factors and controls gene expression via 8-bp ATF/CREB motifs either as a homodimer or as a heterodimer-for instance, with Jun-but has never been shown to be directly involved in oncogenesis. Experiments were designed to evaluate a possible role of ATF2 in oncogenesis in chick embryo fibroblasts (CEFs) in the presence or absence of v-Jun. We found that (i) forced expression of ATF2 cannot alone cause transformation, (ii) overexpression of ATF2 plus v-Jun specifically stimulates v-Jun-induced growth in medium with a reduced amount of serum, and (iii) the efficiency of low-serum growth correlates with the activity of a Jun-ATF2-dependent model promoter in stably transformed CEFs. Analysis of ATF2 and Jun dimerization mutants showed that the growth-stimulatory effect of ATF2 is likely to be mediated by v-Jun-ATF2 heterodimers since (i) v-Jun-m1, a mutant with enhanced affinity for ATF2, induces growth in low-serum medium much more efficiently than v-Jun, when expressed alone or in combination with ATF2; and (ii) ATF2/fos, a mutant that efficiently binds to v-Jun but is unable to form stable homodimers, shows enhanced oncogenic cooperation with v-Jun. In addition, we examined the role of ATF2 in tumor formation by subcutaneous injection of CEFs into chickens. In contrast to v-Jun, v-Jun-m1 gave rise to numerous fibrosarcomas while coexpression of ATF2 and v-Jun-m1 led to a dramatic development of fibrosarcomas visible within 1 week. Together these data demonstrate that overexpressed ATF2 potentiates the ability of v-Jun-transformed CEFs to grow in low-serum medium in vitro and contributes to the formation of tumors in vivo.


Assuntos
Divisão Celular/genética , Proteína de Ligação ao Elemento de Resposta ao AMP Cíclico/genética , Substâncias de Crescimento/genética , Neoplasias Experimentais/genética , Proteína Oncogênica p65(gag-jun)/genética , Fatores de Transcrição/genética , Fator 2 Ativador da Transcrição , Animais , Embrião de Galinha , Proteínas de Ligação a DNA/genética , Regulação da Expressão Gênica/genética , Zíper de Leucina/fisiologia , Dados de Sequência Molecular , Proteínas Oncogênicas , Proteínas Proto-Oncogênicas c-fos/genética , Proteínas Recombinantes de Fusão/genética , Ativação Transcricional/genética
5.
Mol Cell Biol ; 20(22): 8480-8, 2000 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11046144

RESUMO

The transcription factor c-Jun is critically involved in the regulation of proliferation and differentiation as well as cellular transformation induced by oncogenic Ras. The signal transduction pathways that couple Ras activation to c-Jun phosphorylation are still partially elusive. Here we show that an activated version of the Ras effector Rlf, a guanine nucleotide exchange factor (GEF) of the small GTPase Ral, can induce the phosphorylation of serines 63 and 73 of c-Jun. In addition, we show that growth factor-induced, Ras-mediated phosphorylation of c-Jun is abolished by inhibitory mutants of the RalGEF-Ral pathway. These results suggest that the RalGEF-Ral pathway plays a major role in Ras-dependent c-Jun phosphorylation. Ral-dependent regulation of c-Jun phosphorylation includes JNK, a still elusive JNKK, and possibly Src.


Assuntos
Proteínas Quinases Ativadas por Mitógeno/metabolismo , Fator ral de Troca do Nucleotídeo Guanina/metabolismo , Proteínas ras/metabolismo , Animais , Diferenciação Celular/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Linhagem Celular/efeitos dos fármacos , Ativação Enzimática , Fatores de Troca do Nucleotídeo Guanina , Humanos , Insulina/metabolismo , Insulina/farmacologia , Proteínas Quinases JNK Ativadas por Mitógeno , MAP Quinase Quinase 4 , Camundongos , Quinases de Proteína Quinase Ativadas por Mitógeno/metabolismo , Mutação , Fosforilação , Pirazóis/farmacologia , Pirimidinas/farmacologia , Serina , Transdução de Sinais , Fatores de Transcrição/genética , Fatores de Transcrição/metabolismo , Proteínas ral de Ligação ao GTP/metabolismo , Quinases da Família src/antagonistas & inibidores , Quinases da Família src/metabolismo
6.
Mol Cell Biol ; 10(11): 5857-64, 1990 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-2172787

RESUMO

The adenovirus early region 1A (E1A) oncogene interferes with the expression level and activity of the AP-1 transcription factor family. E1A abolished the transactivating function of AP-1 (Jun/Fos), which binds to the 12-O-tetradecanoylphorbol-13-acetate-responsive element of the collagenase gene (collTRE). In contrast, the activity of another member of the AP-1 family that binds to the c-junTRE was not repressed. The mRNA expression of the c-jun gene was, in fact, strongly elevated in various cell types expressing the E1A gene of either adenovirus type 5 (Ad5) or Ad12. The regulation of the junB gene by adenovirus E1A, on the other hand, depended both on the cell type and on the transforming adenovirus serotype. The fact that E1A-induced alterations in the repertoire of AP-1 transcription factors depend on its transforming domain in conserved region 1 suggests that the effects are relevant for the transformation process.


Assuntos
Adenovírus Humanos/genética , Transformação Celular Neoplásica , Proteínas de Ligação a DNA/genética , Proteínas Oncogênicas Virais/genética , Oncogenes , Fatores de Transcrição/genética , Proteínas Precoces de Adenovirus , Animais , Linhagem Celular , Humanos , Mutação , Polyomavirus/genética , Regiões Promotoras Genéticas , Proteínas Proto-Oncogênicas c-jun , Proto-Oncogenes , RNA Mensageiro/genética , Vírus 40 dos Símios/genética
7.
Radiat Res ; 166(1 Pt 1): 81-8, 2006 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-16808623

RESUMO

In 2001, at the TRIGA reactor of the University of Pavia (Italy), a patient suffering from diffuse liver metastases from an adenocarcinoma of the sigmoid was successfully treated by boron neutron capture therapy (BNCT). The procedure involved boron infusion prior to hepatectomy, irradiation of the explanted liver at the thermal column of the reactor, and subsequent reimplantation. A complete response was observed. This encouraging outcome stimulated the Essen/Petten BNCT group to investigate whether such an extracorporal irradiation could be performed at the BNCT irradiation facility at the HFR Petten (The Netherlands), which has very different irradiation characteristics than the Pavia facility. A computational study has been carried out. A rotating PMMA container with a liver, surrounded by PMMA and graphite, is simulated using the Monte Carlo code MCNP. Due to the rotation and neutron moderation of the PMMA container, the initial epithermal neutron beam provides a nearly homogeneous thermal neutron field in the liver. The main conditions for treatment as reported from the Pavia experiment, i.e. a thermal neutron fluence of 4 x 10(12) +/- 20% cm(-2), can be closely met at the HFR in an acceptable time, which, depending on the defined conditions, is between 140 and 180 min.


Assuntos
Desenho Assistido por Computador , Neoplasias Hepáticas/radioterapia , Neoplasias Hepáticas/secundário , Modelos Biológicos , Radiometria/métodos , Planejamento da Radioterapia Assistida por Computador/métodos , Irradiação Corporal Total/instrumentação , Simulação por Computador , Desenho de Equipamento , Análise de Falha de Equipamento , Humanos , Neoplasias Hepáticas/fisiopatologia , Nêutrons/uso terapêutico , Dosagem Radioterapêutica , Rotação , Irradiação Corporal Total/métodos
8.
Oncogene ; 20(19): 2453-64, 2001 Apr 30.
Artigo em Inglês | MEDLINE | ID: mdl-11402340

RESUMO

Jun : Fos and Jun : ATF complexes represent two classes of AP-1 dimers that (1) preferentially bind to either heptameric or octameric AP-1 binding sites, and (2) are differently regulated by cellular signaling pathways and oncogene products. To discriminate between the functions of Jun : Fos, Jun : ATF and Jun : Jun, mutants were developed that restrict the ability of Jun to dimerize either to itself, or to Fos(-like) or ATF(-like) partners. Introduction of these mutants in chicken embryo fibroblasts shows that Jun : Fra2 and Jun : ATF2 dimers play distinct, complementary roles in in vitro oncogenesis by inducing either anchorage independence or growth factor independence, respectively. v-Jun : ATF2 rather than v-Jun : Fra2 triggers the development of primary fibrosarcomas in the chicken wing. Genes encoding extracellular matrix components seem to constitute an important subset of v-Jun : ATF2-target genes. Repression of the matrix component SPARC by Jun is essential for the induction of fibrosarcomas. Avian primary cells transformed by either Jun : Fra2 or Jun : ATF2 thus provide powerful tools for the investigation of the downstream pathways involved in oncogenesis. Further genetic studies with Jun dimerization mutants will be required to be precise and extend the specific roles of the Jun : Fos and Jun : ATF dimers during cancer progression in avian and mammalian systems.


Assuntos
Transformação Celular Neoplásica , Proteína de Ligação ao Elemento de Resposta ao AMP Cíclico/fisiologia , Neoplasias/etiologia , Proteínas Proto-Oncogênicas c-fos/fisiologia , Proteínas Proto-Oncogênicas c-jun/fisiologia , Fatores de Transcrição/fisiologia , Fator 2 Ativador da Transcrição , Animais , Embrião de Galinha , Dimerização , Zíper de Leucina , Modelos Biológicos , Proteínas Proto-Oncogênicas/metabolismo , Proteínas Proto-Oncogênicas c-fos/química , Proteínas Proto-Oncogênicas c-jun/química , Fator de Transcrição AP-1/química , Fator de Transcrição AP-1/fisiologia , Ativação Transcricional
9.
Oncogene ; 20(9): 1135-41, 2001 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-11314051

RESUMO

Activating Transcription Factor 3 (ATF3) is a member of the bZip family of transcription factors. Previous studies in mammalian cells suggested that like other bZip family members e.g. Jun and Fos, ATF3 might play a role in the control of cell proliferation and participate in oncogenic transformation. To investigate this putative ATF3 function directly, the rat ATF3 protein was compared with v-Jun for its ability to transform primary cultures of chick embryo fibroblasts (CEFs). Like CEFs accumulating v-Jun, CEFs accumulating the ATF3 protein displayed a typical, fusiform morphology, associated with an enhanced capacity to grow in medium with reduced amount of serum. However, in contrast to v-Jun-transformed CEFs, the ATF3 overexpressing cells could not promote colony formation from single cells in agar. Partial transformation induced by ATF3 was found to be associated with repression of multiple cellular genes that are also down-regulated by v-Jun, including those coding for the extracellular components fibronectin, decorin, thrombospondin 2, and the pro-apoptotic protein Par-4. These data demonstrate that, at least in primary avian cells, rat ATF3 possesses an intrinsic oncogenic potential. Moreover, the results suggest that ATF3 might induce growth factor independence by down-regulating a subset of the genes repressed by v-Jun.


Assuntos
Transformação Celular Neoplásica/metabolismo , Fibroblastos/metabolismo , Peptídeos e Proteínas de Sinalização Intracelular , Zíper de Leucina/fisiologia , Retroviridae/genética , Fatores de Transcrição/metabolismo , Fatores de Transcrição/fisiologia , Fator 3 Ativador da Transcrição , Animais , Proteínas Reguladoras de Apoptose , Northern Blotting , Proteínas de Transporte/metabolismo , Divisão Celular/fisiologia , Transformação Celular Neoplásica/genética , Transformação Celular Neoplásica/patologia , Embrião de Galinha , Ensaio de Unidades Formadoras de Colônias , Proteínas de Ligação a DNA/metabolismo , Decorina , Regulação para Baixo , Proteínas da Matriz Extracelular , Fibroblastos/patologia , Fibronectinas/metabolismo , Regulação da Expressão Gênica/genética , Regiões Promotoras Genéticas , Proteoglicanas/metabolismo , Proteínas Proto-Oncogênicas c-jun/fisiologia , Ratos , Trombospondinas/metabolismo
10.
Oncogene ; 4(10): 1207-12, 1989 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-2529466

RESUMO

The growth factor-inducible cellular genes JE, c-myc and stromelysin (sml) are strongly repressed upon transformation by adenovirus E1A. As E1A proteins are multifunctional and apparently contain distinct domains (conserved regions 1, 2 and 3), each with a specific effect on gene regulation and cell-transformation, we have investigated which of the three conserved regions are responsible for the reduced expression of these genes. To this end, we monitored the expression of the JE, sml and c-myc genes in a panel of normal rat kidney (NRK) cells expressing different mutant E1A genes. Only CR1, and not CR2 or CR3 were found to be essential for the repression of the genes, indicating that CR1, one of the regions essential for cell transformation, represents an autonomous gene regulatory function that can operate in the absence of CR2. We also show that the association of E1A proteins to a 300 kD cellular protein in NRK cells coincides with the ability to repress these genes.


Assuntos
Glicoproteínas/genética , Substâncias de Crescimento/farmacologia , Metaloendopeptidases/genética , Proteínas Oncogênicas Virais/fisiologia , Proteínas Proto-Oncogênicas/genética , Proto-Oncogenes , Proteínas Repressoras/fisiologia , Fatores de Transcrição/fisiologia , Proteínas Precoces de Adenovirus , Animais , Quimiocina CCL2 , Metaloproteinase 3 da Matriz , Mutação , Proteínas Proto-Oncogênicas c-myc , RNA Mensageiro/análise , Ratos
11.
Oncogene ; 8(7): 1765-73, 1993 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-8510923

RESUMO

Adenovirus-(Ad)- E1A proteins carry two conserved domains (CR1 and CR2) required for transformation of primary rodent cells and essential for association with cellular proteins, including p105RB, p58cyclin A and p33cdk2. We show that in normal rat kidney 49F (NRK) cell lines expressing various mutant Ad5-E1A genes, CR2-, but not CR-1-, deletion mutants induce a typical transformed phenotype as characterized by morphology, absence of density arrest and loss of serum requirement. This indicates that induction of these transformed properties is a function of CR1. The fact that E1A proteins with deletions in CR2 show a greatly reduced association with RB, cyclin A and p33cdk2 suggests that these associations are dispensable for E1A-mediated transformation of NRK cells. Induction of the transformed properties is accompanied by a CR1-dependent increase in Proliferating Cell Nuclear Antigen and cyclin A gene expression. Elevated mRNA and protein levels of cyclin A were also found in Ad12-E1-transformed NRK cells but not in ras-transformed NRK cells. On the other hand, cyclin D expression is decreased in a CR1-dependent manner. Although Ad5-E1A proteins are sufficient to transform NRK cells, further deregulation of growth is obtained when Ad5-E1B proteins are co-expressed. One of the Ad5-E1B effects is the sequestration of the p53 protein into a cytoplasmic body containing the p53/Ad5-E1B-55 kD complex. Interestingly, in NRK cell lines expressing Ad5-E1B-55 kD, cyclin A could be detected not only in the nucleus but also in the cytoplasmic bodies. These results indicate that the deregulation of cell cycle control by the Adenovirus-E1 region may be due to a CR1-dependent alteration of the expression of cyclins A and D.


Assuntos
Proteínas E1A de Adenovirus/genética , Transformação Celular Neoplásica/metabolismo , Ciclinas/análise , Proteínas E1A de Adenovirus/química , Sequência de Aminoácidos , Animais , Linhagem Celular Transformada , Dados de Sequência Molecular , Mutação , Ratos , Relação Estrutura-Atividade
12.
Oncogene ; 6(6): 911-6, 1991 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-1906158

RESUMO

The expression of the junB gene parallels the expression of the MHC class I genes in Adenovirus (Ad) transformed cells. In Ad12E1-transformed primary BRK cells both genes are transcriptionally repressed only when the 13S product of Ad12E1A is present. This indicates that repression of MHC class I and junB genes is a function of conserved region 3 (CR3) of the Ad12E1A protein. In Ad5-transformed BRK cells expression of these genes is unchanged. In established NRK cells, however, introduction of Ad12E1A does not cause repression of the MHC class I and junB genes, but in these cells Ad5E1A increases the expression of both MHC class I and junB. Using mutant Ad5E1A genes, it is shown that this activation is mediated by CR1. Introduction of a functional junB gene under the control of a heterologous promoter in Ad12E1-transformed BRK cells causes no increase in MHC class I expression. This demonstrates that the down-regulation of junB is not directly responsible for class I repression, but rather that both genes are coregulated by the Ad12E1 region.


Assuntos
Adenovírus Humanos/genética , Proteínas de Ligação a DNA/genética , Regulação Viral da Expressão Gênica , Genes MHC Classe I/fisiologia , Antígenos de Histocompatibilidade Classe I/genética , Fatores de Transcrição/genética , Adenovírus Humanos/metabolismo , Adenovírus Humanos/fisiologia , Animais , Sequência de Bases , Linhagem Celular Transformada , Proteínas de Ligação a DNA/metabolismo , Regulação para Baixo/genética , Antígenos de Histocompatibilidade Classe I/metabolismo , Humanos , Dados de Sequência Molecular , Regiões Promotoras Genéticas/genética , Proteínas Proto-Oncogênicas c-jun , Fatores de Transcrição/metabolismo , Transcrição Gênica/genética
13.
Oncogene ; 18(14): 2311-21, 1999 Apr 08.
Artigo em Inglês | MEDLINE | ID: mdl-10327051

RESUMO

The adenovirus E1A proteins activate the c-jun promoter through two Jun/ATF-binding sites, jun1 and jun2. P300, a transcriptional coactivator of several AP1 and ATF transcription factors has been postulated to play a role in this activation. Here, we present evidence that p300 can control c-jun transcription by acting as a cofactor for ATF2: (1) Over-expression of p300 was found to stimulate c-jun transcription both in the presence and absence of E1A. (2) Like E1A, p300 activates the c-jun promoter through the junl and jun2 elements and preferentially activates the N-terminal domain of ATF2. (3) Co-immunoprecipitation assays of crude cell extracts indicate that endogenous p300/CBP(-like) proteins and ATF2 proteins are present in a multiprotein complex that can bind specifically to the jun2 element. We further demonstrate that the Stress-Activated-Protein-Kinase (SAPK) target sites of ATF2, Thr69 and Thr71 are not required for the formation of the p300/CBP-ATF2 multiprotein complex. These data indicate that E1A does not inhibit all transcription activation functions of p300, and, in fact, cooperates with p300 in the activation of the ATF2 N-terminus.


Assuntos
Proteínas E1A de Adenovirus/fisiologia , Proteína de Ligação ao Elemento de Resposta ao AMP Cíclico/metabolismo , Regulação Viral da Expressão Gênica , Genes jun , Proteínas Quinases Ativadas por Mitógeno , Proteínas Nucleares/fisiologia , Regiões Promotoras Genéticas , Transativadores/fisiologia , Fatores de Transcrição/metabolismo , Ativação Transcricional , Fator 2 Ativador da Transcrição , Animais , Sítios de Ligação , Proteínas Quinases Dependentes de Cálcio-Calmodulina/fisiologia , Linhagem Celular Transformada , Humanos , Substâncias Macromoleculares , Proteína Quinase 12 Ativada por Mitógeno , Proteína Quinase 9 Ativada por Mitógeno , Complexos Multiproteicos , Proteínas Nucleares/genética , Fosfotreonina/metabolismo , Proteínas Quinases/fisiologia , Processamento de Proteína Pós-Traducional , Proteínas Recombinantes de Fusão/fisiologia , Sequências Reguladoras de Ácido Nucleico , Transativadores/genética , Proteínas Quinases p38 Ativadas por Mitógeno
14.
Radiat Prot Dosimetry ; 115(1-4): 408-11, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16381756

RESUMO

A study is being performed on the properties of the Geel Electron Linear Accelerator (GELINA), a powerful white neutron source, designed for the high-energy resolution time-of-flight measurements. The main aim of this study is to reduce the time spread of neutrons of the given energy without compromising the neutron yield. Both time spread and neutron intensity influence the experimental accuracy of high-resolution neutron cross section measurements, which are particularly important in the resonance region. The quantities of interest have been simulated with coupled electron-photon-neutron steady state and transient MCNP4C3 calculations. Following benchmarking of the code to the properties of the existing target, neutron yield, energy spectra, resolution functions, and neutron and heat spatial distributions have been determined for various alternative geometries and materials. At a fixed accelerator power, actinides deliver the highest neutron yield and a small target provides the best time resolution. The resulting high-power density requires a joint optimisation of the thermal hydraulics and neutronics properties.


Assuntos
Desenho Assistido por Computador , Método de Monte Carlo , Nêutrons , Aceleradores de Partículas/instrumentação , Radiometria/métodos , Desenho de Equipamento/métodos , Análise de Falha de Equipamento/métodos , Modelos Estatísticos , Controle de Qualidade , Doses de Radiação , Radiometria/instrumentação , Software
15.
J Med Chem ; 23(8): 889-95, 1980 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-6105218

RESUMO

Ultraviolet photoelectron spectroscopy (UV PES) and CNDO/s molecular orbital calculations have been employed to investigate the electronic structure of clonidine and some other 2-(phenylimino)imidazolidines. The assignment of the bands in the spectra to particular molecular orbitals is based on the CNDO/s results in conjunction with Koopmans' theorem, substituent effects, and differences in intensity between the He (I) and He(II) spectra. The location of the energy levels of orbitals with mainly nN and delta character is not correctly estimated estimated by CNDO/s, while the pi orbital energy levels are satisfactorally predicted. The UV PES and CNDO/s results indicate in contrast investigated 2-(phenylimino)imidazolidines, which may indicate that differences in hypotensive activity cannot be ascribed to variations in steric hindrance within the molecules. The first ionization energies of the pharmacologically active 20-(phenylimino)imidazolidines do not correlate with hypotensive activity based on dosage data after intravenous administration to rats.


Assuntos
Antagonistas Adrenérgicos alfa , Clonidina , Imidazóis , Fenômenos Químicos , Química , Teoria Quântica , Análise Espectral/métodos , Raios Ultravioleta
16.
Photochem Photobiol ; 55(3): 409-15, 1992 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-1561239

RESUMO

In HeLa cells transcription of the c-jun gene is activated strongly and rapidly by ultraviolet (UV) irradiation and, to a somewhat lesser extent, by treatment with phorbol ester tumor promoters. In the same cells UV and phorbol esters only marginally enhance the abundance of RNA transcribed from the jun D gene and from the gene coding for the serum response factor (which in turn acts on the UV and phorbol ester response element of the c-fos gene). In contrast to c-jun, jun B transcription is induced more efficiently by phorbol ester than by UV irradiation, suggesting that the members of the jun family are differently regulated. The promoter of c-jun carries two enhancer elements resembling AP-1 binding sites: the jun1 UV response element (URE-71 TGACATCA -64) and the jun2 URE (-190 TTACCTCA-183). These elements act independently in the UV induced expression of c-jun. In the context of the complete c-jun promoter they seem not to be required for c-jun induction by phorbol esters. When fused to the Herpes simplex thymidine kinase promoter, however, the isolated elements mediate induction by both UV and phorbol esters. UV and phorbol ester treatment of cells increases the binding of transcription factors to both elements. Both elements bind factors different in modification or/and constitution from AP-1, the heterodimeric transcription factor composed of c-Fos and c-Jun that controls the activity of the UV and phorbol ester response element (-72 TGAGTCA-66) of the human collagenase gene.


Assuntos
Genes jun/efeitos da radiação , Proteínas Proto-Oncogênicas c-jun/metabolismo , Transcrição Gênica/efeitos da radiação , Sequência de Bases , Sítios de Ligação , DNA/genética , DNA/efeitos da radiação , Genes jun/efeitos dos fármacos , Células HeLa , Humanos , Dados de Sequência Molecular , Fotoquímica , Biossíntese de Proteínas , Acetato de Tetradecanoilforbol/farmacologia , Transcrição Gênica/efeitos dos fármacos , Raios Ultravioleta
17.
Phys Med Biol ; 49(18): 4277-92, 2004 Sep 21.
Artigo em Inglês | MEDLINE | ID: mdl-15509065

RESUMO

The values of the parameters used in boron neutron capture therapy (BNCT) to calculate a given dose to human tissue vary with patients due to different physical, biological and/or medical circumstances. Parameters include the tissue dimensions, the 10B concentration and the relative biological effectiveness (RBE) factors for the different dose components associated with BNCT. Because there is still no worldwide agreement on RBE values, more often than not, average values for these parameters are used. It turns out that the RBE-problem can be circumvented by taking into account all imaginable parameter values. Approaching this quest from another angle: the outcome will also provide the parameters (and values) which influence the optimal source neutron energy. For brain tumours it turns out that the 10B concentration, the RBE factors for 10B as well as fast neutrons, together with the dose limit set for healthy tissue, affect the optimal BNCT source neutron energy. By using source neutrons of a few keV together with neutrons of a few eV, it ensures that, under all imaginable circumstances, a maximum of alpha (and lithium) particles can be delivered in the tumour.


Assuntos
Algoritmos , Terapia por Captura de Nêutron de Boro/métodos , Neoplasias Encefálicas/fisiopatologia , Neoplasias Encefálicas/radioterapia , Modelos Biológicos , Radiometria/métodos , Planejamento da Radioterapia Assistida por Computador/métodos , Animais , Carga Corporal (Radioterapia) , Simulação por Computador , Humanos , Transferência Linear de Energia/fisiologia , Modelos Estatísticos , Método de Monte Carlo , Especificidade de Órgãos , Garantia da Qualidade dos Cuidados de Saúde/métodos , Dosagem Radioterapêutica , Eficiência Biológica Relativa
18.
Environ Pollut ; 78(1-3): 165-71, 1992.
Artigo em Inglês | MEDLINE | ID: mdl-15091943

RESUMO

Liming experiments with powdered limestone (grain size < 3 mm) were conducted in eight acid shallow moorland pools in the Tongerense Heide heathland area from February 1988 until November 1989. The effects on water chemistry, diatoms and fungal infection of the eggs of the moor frog were studied. After an initial treatment in March 1988, the pH increased from c. 4.0 to c. 5.0 in those pools which dried out in summer and to c. 6.0 in the permanent pools. Alkalinity increased from 0 to 20-200 microeq litre(-1) in temporary pools and from 0 to 300-500 microeq litre(-1) in permanent pools. As drying out of the pools caused reacidification, after refilling the temporary pools were relimed in March 1989. No significant changes were found in concentrations of phosphate and nitrogen compounds. Eunotia paludosa, which is characteristic for ologotrophic, very acid pools and bogs with a fluctuating water table, was the dominant diatom in the untreated pools. It was replaced by eutraphentic and saprophilous taxa, particularly in the permanent pools. Species from extremely soft waters, which are very sensitive to acidification, were found only occasionally in some samples from the treated permanent pools. After liming the proportion of infected moor frog eggs decreased from c. 95% in the untreated to c. 5% in the treated pools.

19.
J Am Psychoanal Assoc ; 35(3): 647-55, 1987.
Artigo em Inglês | MEDLINE | ID: mdl-3611586

RESUMO

This paper describes an example of acting out of countertransference during a brief but unexpected serious illness. My emphasis is on the regression that occurred with hospitalization and how it dovetailed with a particular patient's transference. A confluence of my residual neurosis, the patient's neurosis, her transference state, her other characteristics (that she was female, for example), plus the fact that she was the last patient contacted, all conspired with the regression from the trauma of being hospitalized to produce the countertransference reaction. This presentation is also intended to add to the very sparse literature on a distasteful subject of supreme importance.


Assuntos
Contratransferência , Terapia Psicanalítica , Papel do Doente , Humanos , Relações Profissional-Paciente , Eosinofilia Pulmonar/psicologia , Transferência Psicológica
20.
Tijdschr Diergeneeskd ; 113(23): 1285-98, 1988 Dec 01.
Artigo em Holandês | MEDLINE | ID: mdl-3061065

RESUMO

Recombinant Bovine Somtatotropin (r-BST) may be produced commercially in the forseeable future. On the basis of a study of the literature, it may be assumed in all likelihood that administration of r-BST to dairy cows will not have a negative effect on public health. However additional research on potential biological activity of recombinant-BST or its fragments and of somatomedins after oral administration, is advisable. Negative effects on the health, fertility and life-span of animals were not observed so far under experimental conditions but any reference to field situations is absent in the literature. Treatment with r-BST should not be initiated prior to within eighty days after parturition. Administration of r-BST also requires proper management in terms of ration formulation and feeding to ensure maintenance of health and production of dairy cattle. The use of r-BST will result in a less accurate estimation of the breeding potential of selected cows, resulting in a reduction of the genetic improvement of milk production. Increased economic benefits should be obtained on farms having high stocking rates (2.35 dairy cows/ha) compared with those having low stocking rates (1.90), varying with the price of r-BST. It is anticipated that the use of r-BST will have little effect on the reduction of the number of dairy cattle and dairy farms up to 1995.


Assuntos
Criação de Animais Domésticos/economia , Hormônio do Crescimento/administração & dosagem , Lactação/efeitos dos fármacos , Saúde Pública , Fenômenos Fisiológicos da Nutrição Animal/efeitos dos fármacos , Animais , Cruzamento , Bovinos , Resíduos de Drogas/efeitos adversos , Feminino , Fertilidade/efeitos dos fármacos , Hormônio do Crescimento/farmacologia , Humanos , Metabolismo/efeitos dos fármacos , Gravidez , Proteínas Recombinantes/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA